Joseph Pantginis, an analyst from H.C. Wainwright, maintained the Buy rating on BioCardia. The associated price target remains the same with $25.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Joseph Pantginis has given his Buy rating due to a combination of factors related to BioCardia’s strategic advancements and potential regulatory milestones. The company is making significant progress with its CardiAMP HF program, particularly in the U.S. and Japan, where it is focusing on clinical and regulatory pathways. The anticipated consultations with the PMDA in Japan and a meeting request with the FDA in the U.S. highlight the company’s proactive approach in seeking approvals for its cell therapy.
Moreover, BioCardia’s financial position appears stable, with a cash runway extending into the second quarter of 2026, which supports its ongoing clinical trials and regulatory efforts. The company’s proprietary biotherapeutic delivery device, which is expected to strengthen its financial standing, is also a key factor in Pantginis’s positive outlook. Despite not meeting the primary endpoint in a previous trial, the ongoing CardiAMP HF II trial and other clinical programs, like CardiALLO, show promise in advancing BioCardia’s therapeutic offerings.
Pantginis covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, Celldex, and Travere Therapeutics. According to TipRanks, Pantginis has an average return of 2.2% and a 44.09% success rate on recommended stocks.